PBYI today
$8.19+$0.11 (+1.36%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourExpanding
1 hourLeaning Bullish
15 minBullish
5 minStrong Bullish
Daily trend turns down below $9.74
Key levels
Resistance$9.74
Resistance$9.02
Support$8.12
Support$7.41
Latest news & SEC filings
EarningsPuma Biotechnology Posts Q3 2026 Financial Results
EarningsPuma Biotechnology holds Q3 2026 earnings call
GuidancePuma Biotechnology trims FY2026 sales guidance to $224M-$227M
All PBYI news →About Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on cancer treatments. It markets NERLYNX, an oral drug for certain HER2-positive breast cancers, in the United States through its own sales team and elsewhere via sub-licensees. The company also develops alisertib, an investigational Aurora Kinase A inhibitor, for several cancer types.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
PUMA BIOTECHNOLOGY, INC. (PBYI)
What Is the Price Target for PBYI?
SEPT Low Target
$6.00
SEPT Mid Target
$6.00
SEPT High Target
$6.00
Analyst Consensus
$6.00
Is PBYI a Buy or Sell Right Now?
Thesis
- •Revenue growing -0.9% YoY with SLOWING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PBYI.
Start Free Trial →Is PBYI Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$6.30
35
Moat Score
NONE
6/9
Piotroski Score
-2.5
Altman Z-Score
What Is Smart Money Doing with PBYI?
Insider Signal
SELLING
0 buys / 10 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| WILSON TROY EDWARD | director | Sale | 10,800 | $78K | Jun 12, 2026 |
| Stuglik Brian M | director | Sale | 8,100 | $58K | Jun 12, 2026 |
| Senderowicz Adrian | director | Sale | 27,000 | $194K | Jun 12, 2026 |
| MOYES JAY M | director | Sale | 22,000 | $159K | Jun 12, 2026 |
| Dorval Allison | director | Sale | 11,610 | $84K | Jun 12, 2026 |
| WILSON TROY EDWARD | director | Buy | 27,000 | - | Jun 11, 2026 |
| Stuglik Brian M | director | Buy | 27,000 | - | Jun 11, 2026 |
| Senderowicz Adrian | director | Buy | 27,000 | - | Jun 11, 2026 |
| MILLER MICHAEL PATRICK | director | Buy | 27,000 | - | Jun 11, 2026 |
| MOYES JAY M | director | Buy | 27,000 | - | Jun 11, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PBYI Growth Story
Revenue YoY
-0.9%
3yr Revenue CAGR
0.1%
EPS Growth YoY
-1.61%
FCF Growth YoY
7.4%
Revenue Trend
SLOWING
Dark Pool Trades for PBYI
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PBYI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:54:19 | $8.18 | 1,100 | $$9K | BUY |
| 16:30:59 | $8.17 | 1,614 | $$13K | SELL |
| 16:30:57 | $8.19 | 5,000 | $$41K | SELL |
| 16:30:55 | $8.19 | 5,000 | $$41K | SELL |
| 16:30:54 | $8.17 | 5,000 | $$41K | SELL |
5 dark pool trades shown · $$145K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for PUMA BIOTECHNOLOGY, INC. (PBYI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (4 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PBYI — frequently asked questions
What is PBYI stock price today?
PUMA BIOTECHNOLOGY, INC. (PBYI) is at $8.19, up 1.36% (+$0.11) at the Nov 12, 2026 close.
Why is PBYI stock moving today?
Latest PBYI news — Nov 5, 2026: Puma Biotechnology Posts Q3 2026 Financial Results · Nov 5, 2026: Puma Biotechnology holds Q3 2026 earnings call
What is the PBYI price target?
The average analyst price target for PBYI is $6.00, ranging from $6 to $6, based on 1 analysts. Latest: TD Cowen maintains on Aug 7, 2026.
What do analysts rate PBYI?
Analyst ratings for PBYI: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did PBYI beat earnings?
PBYI last reported on Aug 6, 2026: EPS $0.20 vs $0.05 expected — a beat of 300.0%.
What is PBYI's P/E ratio?
PBYI trades at a P/E of 18.8 vs a Healthcare average of 17.9.
Does PBYI pay a dividend?
PBYI does not currently pay a dividend.
What are PBYI support and resistance levels?
Support: $8.12, $7.41, $6.78. Resistance: $9.02, $9.74, $10.49.
What are insiders doing with PBYI?
Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.
What is the latest news on PBYI?
Nov 5, 2026: Puma Biotechnology Posts Q3 2026 Financial Results · Nov 5, 2026: Puma Biotechnology holds Q3 2026 earnings call · Nov 5, 2026: Puma Biotechnology trims FY2026 sales guidance to $224M-$227M